Negligible effect of tenofovir on atazanavir trough concentrations and genotypic inhibitory quotients in the presence and absence of ritonavir

Therapeutic Drug Monitoring

Volumn 35, Issue 2, 2013, Pages 264-269

  Fournier, Cassandra ^a   Higgins, Niamh ^b   Thomas, Réjean ^c   Baril, Jean Guy ^d   Thibeault, Denis ^b   Lalonde, Richard ^b   Sheehan, Nancy L ^a,b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c Clinique Medicale l'Actuel   (Canada)

^d Clinique du Quartier Latin   (Canada)

Author keywords

atazanavir; drug interaction; tenofovir; therapeutic drug monitoring

Indexed keywords

ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; TENOFOVIR DISOPROXIL;

ADULT; ARTICLE; CONFIDENCE INTERVAL; DATA BASE; DRUG EFFECT; DRUG MONITORING; FEMALE; GENOTYPIC INHIBITORY QUOTIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; RISK; SCREENING; STATISTICAL SIGNIFICANCE; TROUGH CONCENTRATION; UNSPECIFIED SIDE EFFECT; VIRUS LOAD;

ADENINE; ADULT; DRUG INTERACTIONS; DRUG MONITORING; FEMALE; GENOTYPE; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; OLIGOPEPTIDES; ORGANOPHOSPHONATES; PYRIDINES; RETROSPECTIVE STUDIES; RITONAVIR; VIRAL LOAD;

EID: 84875158790     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3182834057     Document Type: Article

References (19)

1. Kaul S, Bassi K, Damle B, et al. Pharmacokinetic (PK) evaluation of the combination of atazanavir (ATV), enteric coated didanosine (ddI-EC), and tenofovir disoproxil fumarate (TDF) for a once-daily antiretroviral regimen. Presented at: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 14-17 September 2003; Chicago, IL.
2. Gonzalez de Requena D, Bonora S, Cavechia I, et al. Atazanavir Ctrough is associated with efficacy and safety at 24 weeks: definition of therapeutic range. Presented at: 6th International Workshop on Clinical Pharmacology of HIV Therapy; 28-30 April 2005; Quebec City, Canada.
3. Higgins N, Tseng A, Sheehan NL, et al. Antiretroviral therapeutic drug monitoring in Canada: current status and recommendations for clinical practice. Can J Hosp Pharm. 2009; 62: 500-509.
4. Reyataz (R) [Product Monograph]. Princeton, NJ: Bristol-Myers Squibb; 2010.
5. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: 2004. Top HIV Med. 2004; 12: 119-124.
6. STATA. 11.1 ed. College Station, TX: StataCorp LP; 2009.
7. Molto J, Santos JR, Valle M, et al. Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice. Ther Drug Monit. 2007; 29: 648-651.
8. Acosta EP. Pharmacokinetic enhancement of protease inhibitors. J Acquir Immune Defic Syndr. 2002; 29(suppl 1): S11-S18.
9. Kempf DJ, Marsh KC, Kumar G, et al. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother. 1997; 41: 654-660.
10. Calcagno A, Bonora S, Tettoni MC, et al. Tenofovir coadministration is not associated with lower unboosted atazanavir plasma exposure in the clinical setting. J Acquir Immune Defic Syndr. 2009; 52: 431-432.
11. Smyth C, Date HL, Reeves I, et al. Therapeutic drug monitoring (TDM) of atazanavir (ATV) in clinical practice. Presented at: 7th International Workshop on Clinical Pharmacology of HIV Therapy; 20-22 April 2006; Lisbon, Portugal.
12. Barrios A, Rendon AL, Gallego O, et al. Predictors of virological response to atazanavir in protease inhibitor-experienced patients. HIV Clin Trials. 2004; 5: 201-205.
13. Cleijsen RM, van de Ende ME, Kroon FP, et al. Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice. J Antimicrob Chemother. 2007; 60: 897-900.
14. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 1-239. Available at: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed May 13, 2012.
15. Squires KE, Young B, Dejesus E, et al. Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients. HIV Clin Trials. 2010; 24: 2019-2027.
16. Wentzell JR, Kravcik S, Giguère P. Efficacy of boosted and unboosted atazanavir-based therapy in patients without prior antiretroviral treatment failure. Can J Infect Dis Med Microbiol. 2012; 23: 66A.
17. Winston A, Bloch M, Carr A, et al. Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy. J Antimicrob Chemother. 2005; 56: 380-387.
18. Bertz R, Wang Y, Mahnke L, et al. Assessment of pharmacokinetic/ pharmacodynamic relationships through 48 weeks from a study in HIV+, ARTnaive subjects receiving antiretroviral regimens containing atazanavir 400 mg or atazanavir/ritonavir 300/100 mg once daily. Presented at: 14th Conference on Retroviruses and Opportunistic Infections; 25-28 February 2007; Los Angeles, CA.
19. la Porte CJL, Back D, Blaschke T, et al. Updated guidelines to perform therapeutic drug monitoring for antiretroviral agents. Rev Antiviral Ther. 2006; 3: 4-14.